Cellectis S.A. (CLLS) stock
CLLSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 20, 2026Score 3/30
$1.03−0.03 (-2.83%)
Close on Nov 18, 2026Market cap $103.35MP/E –Yield –
Cellectis cash
Cash and short-term investments held at the end of each period.
Cellectis's cash was $35.59M at Jun 30, 2026. For fiscal 2025 it was $61.53M, down 57.0% from the year before. Over ten years it grew -15.8% a year on average. The highest annual figure on record is $451.50M in fiscal 2018.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $61.53M | -57.0% |
| FY2024 | Dec 31, 2024 | $143.25M | +4.8% |
| FY2023 | Dec 31, 2023 | $136.71M | +46.7% |
| FY2022 | Dec 31, 2022 | $93.22M | -49.8% |
| FY2021 | Dec 31, 2021 | $185.64M | -23.0% |
| FY2020 | Dec 31, 2020 | $241.15M | -29.2% |
| FY2019 | Dec 31, 2019 | $340.52M | -24.6% |
| FY2018 | Dec 31, 2018 | $451.50M | +76.1% |
| FY2017 | Dec 31, 2017 | $256.38M | +0.7% |
| FY2016 | Dec 31, 2016 | $254.57M | -25.6% |
| FY2015 | Dec 31, 2015 | $342.11M | +150.8% |
| FY2014 | Dec 31, 2014 | $136.40M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $35.59M | -76.1% |
| Q4 FY2025 | Dec 31, 2025 | $61.53M | -55.0% |
| Q2 FY2025 | Jun 30, 2025 | $59.81M | -29.1% |
| Q4 FY2024 | Dec 31, 2024 | $143.25M | +53.7% |
| Q2 FY2024 | Jun 30, 2024 | $149.04M | +15.1% |
| Q4 FY2023 | Dec 31, 2023 | $136.71M | -26.4% |
| Q2 FY2023 | Jun 30, 2023 | $84.39M | -66.0% |
| Q4 FY2022 | Dec 31, 2022 | $93.22M | -61.3% |
| Q2 FY2022 | Jun 30, 2022 | $129.44M | -50.4% |
| Q4 FY2021 | Dec 31, 2021 | $185.64M | -45.5% |
| Q2 FY2021 | Jun 30, 2021 | $248.23M | -37.5% |
| Q4 FY2020 | Dec 31, 2020 | $241.15M | -46.6% |
| Q2 FY2020 | Jun 30, 2020 | $260.71M | +1.7% |
| Q4 FY2019 | Dec 31, 2019 | $340.52M | +33.8% |
| Q2 FY2019 | Jun 30, 2019 | $396.97M | +16.0% |
| Q4 FY2018 | Dec 31, 2018 | $451.50M | +231.0% |
| Q4 FY2017 | Dec 31, 2017 | $256.38M | – |
| Q4 FY2016 | Dec 31, 2016 | $254.57M | – |
| Q4 FY2015 | Dec 31, 2015 | $342.11M | – |
| Q4 FY2014 | Dec 31, 2014 | $136.40M | – |
See a number that looks wrong?